Akari Narrows Loss to $12M, But Intangible Impairment Hits Q3

TL;DR

**Akari's cash is burning fast, and while losses narrowed, that $5.18M impairment loss is a red flag – stay away until they prove they can fund their pipeline.**

AI Summary

Akari Therapeutics Plc reported a net loss of $12.0 million for the nine months ended September 30, 2025, a significant improvement from the $16.0 million net loss in the same period of 2024. This improvement was primarily driven by a substantial decrease in research and development expenses, which fell from $5.7 million in 2024 to $1.7 million in 2025. However, the company recognized a significant impairment loss on other intangible assets of $5.18 million in the third quarter of 2025, which contributed to a loss from operations of $14.0 million for the nine-month period. General and administrative expenses increased to $7.1 million from $6.6 million year-over-year. Akari's cash position remains precarious, with only $2.48 million in cash as of September 30, 2025, down from $2.59 million at December 31, 2024. The company's total liabilities decreased from $28.3 million at December 31, 2024, to $22.6 million at September 30, 2025, largely due to a gain on settlement of current liabilities of $2.0 million. Akari continues to focus on its ADC platform, utilizing a novel anti-cancer payload called PH1, but acknowledges the need for significant capital expenditures to complete its research and development efforts.

Why It Matters

Akari's ability to reduce its net loss by 25% year-over-year, despite an impairment charge, signals some operational streamlining, which could be a positive for investors. However, the company's critically low cash balance of $2.48 million and ongoing need for significant capital raise serious concerns about its long-term viability and ability to fund its ADC platform development. For employees, this financial instability could mean job insecurity, while customers (future patients) face uncertainty regarding the progression of Akari's novel anti-cancer therapies. In the competitive biotech landscape, Akari's struggle to secure funding and advance its pipeline puts it at a disadvantage against larger, better-capitalized pharmaceutical companies.

Risk Assessment

Risk Level: high — Akari Therapeutics Plc faces a high risk level due to its critically low cash balance of $2.48 million as of September 30, 2025, and a net loss of $12.0 million for the nine months ended September 30, 2025. The company explicitly states it 'will need, among other things, to complete its research and development efforts... and will require significant operating and capital expenditures in the foreseeable future,' indicating a substantial funding gap without clear immediate solutions.

Analyst Insight

Investors should exercise extreme caution and consider avoiding AKTX shares given the severe liquidity constraints and the explicit 'going concern' risk. Monitor for any significant capital raises or strategic partnerships that could provide the necessary funding for their ADC platform, as this would be a critical turning point.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

$22.6M

net Income

-$12.0M

eps

N/A

gross Margin

N/A

cash Position

$2.48M

revenue Growth

N/A

Key Numbers

• $2.48M — Cash (As of September 30, 2025, down from $2.59M at Dec 31, 2024, indicating severe liquidity issues.)
• $12.0M — Net Loss (For the nine months ended September 30, 2025, an improvement from $16.0M in 2024, but still substantial.)
• $5.18M — Impairment Loss on Other Intangible Assets (Recognized in the three months ended September 30, 2025, significantly impacting Q3 results.)
• $1.7M — Research and Development Expenses (For the nine months ended September 30, 2025, a decrease from $5.7M in 2024.)
• $7.1M — General and Administrative Expenses (For the nine months ended September 30, 2025, an increase from $6.6M in 2024.)
• $2.0M — Gain on Settlement of Current Liabilities (For the nine months ended September 30, 2025, contributing to reduced total liabilities.)
• 71,479,461,523 — Ordinary Shares Outstanding (As of November 13, 2025, indicating significant share dilution.)
• $7.5M — Net Cash Used in Operating Activities (For the nine months ended September 30, 2025, highlighting ongoing cash burn.)

Key Players & Entities

• Akari Therapeutics Plc (company) — registrant
• Peak Bio, Inc. (company) — acquired company
• PH1 (other) — novel anti-cancer payload
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Capital Market (other) — stock exchange
• FASB (regulator) — Financial Accounting Standards Board
• ASC 205-40 (other) — accounting standard for going concern

FAQ

Risk Factors

• Liquidity and Going Concern [high — financial]: Akari Therapeutics Plc has a cash position of $2.48 million as of September 30, 2025, which is a decrease from $2.59 million at December 31, 2024. The company has incurred net losses and significant cash burn from operating activities ($7.5 million for the nine months ended September 30, 2025), raising substantial doubt about its ability to continue as a going concern without additional capital.
• Product Development and Clinical Trial Uncertainty [high — operational]: The company is in the pre-clinical and clinical stage of development for its ADC platform utilizing the PH1 payload. There is inherent uncertainty in product development, the success of clinical trials, and obtaining marketing authorization, which could delay or terminate research activities.
• Need for Significant Capital Expenditures [high — financial]: Completing research and development, pre-clinical, regulatory activities, and clinical trials will require significant operating and capital expenditures. The company's current cash position is insufficient to meet these future needs, necessitating the raising of additional capital.
• Competition with Larger Companies [medium — market]: Akari Therapeutics operates in a competitive landscape and faces risks associated with competition from larger, better-capitalized companies that may have more resources for research, development, and commercialization of ADC therapies.
• Dependence on Key Individuals and Third Parties [medium — operational]: The company's success is dependent on key individuals and may also rely on third-party collaborators for research and development operations. Any disruption or loss related to these dependencies could negatively impact the company's progress.
• Intellectual Property Protection [medium — regulatory]: Protecting intellectual property is crucial for a biotechnology company. Risks associated with the protection of patents and proprietary technology for its ADC platform could impact its competitive advantage and future revenue generation.
• Impairment of Intangible Assets [medium — financial]: The company recognized a significant impairment loss on other intangible assets of $5.18 million in the third quarter of 2025. This indicates a potential overvaluation or loss of value in previously recognized intangible assets, impacting current financial performance.

Industry Context

The antibody-drug conjugate (ADC) market is a rapidly evolving segment of the biopharmaceutical industry, characterized by significant innovation and investment. Companies are focused on developing novel payloads and conjugation technologies to improve efficacy and reduce toxicity. The competitive landscape includes both established pharmaceutical giants and emerging biotechnology firms, all vying for market share in oncology.

Regulatory Implications

As a clinical-stage biotechnology company, Akari Therapeutics is subject to stringent regulatory oversight from bodies like the FDA and EMA. Successful development and commercialization hinge on navigating complex clinical trial pathways, demonstrating safety and efficacy, and obtaining marketing authorization, all of which carry significant time and financial risks.

What Investors Should Do

1. Monitor cash burn and future financing needs closely.
2. Evaluate the progress and success of the PH1 payload and ADC platform development.
3. Assess the competitive landscape and Akari's differentiation.
4. Consider the impact of the intangible asset impairment.

Key Dates

• 2024-11-14: Completion of Merger with Peak Bio, Inc. — This strategic business combination marked a significant shift in focus towards Akari's ADC platform utilizing the PH1 payload.

Glossary

ADCs

Antibody-Drug Conjugates are a class of biopharmaceutical drugs composed of monoclonal antibodies linked to potent cytotoxic agents, designed to target cancer cells more specifically. (Akari Therapeutics is developing next-generation ADCs, making this a core technology for the company.)

PH1 payload

A novel anti-cancer payload developed by Akari Therapeutics, described as a spliceosome modulator. (This is the key proprietary component of Akari's ADC platform, central to its product development strategy.)

Spliceosome modulator

A substance that affects the function of the spliceosome, a cellular complex responsible for removing introns from precursor messenger RNA. (This describes the mechanism of action for Akari's PH1 payload, indicating its potential to disrupt cancer cell function.)

Impairment loss

A reduction in the carrying value of an asset on a company's balance sheet when its fair value falls below its book value. (Akari recognized a significant impairment loss of $5.18 million on other intangible assets, impacting its reported net loss.)

Going concern

An accounting assumption that a company will continue to operate for the foreseeable future without the threat of liquidation. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, a critical disclosure for investors.)

Year-Over-Year Comparison

Akari Therapeutics has shown an improvement in its net loss for the nine months ended September 30, 2025, decreasing to $12.0 million from $16.0 million in the prior year. This improvement was largely driven by a substantial reduction in R&D expenses, from $5.7 million to $1.7 million. However, this was offset by a significant $5.18 million impairment loss on other intangible assets in Q3 2025. General and administrative expenses saw a slight increase from $6.6 million to $7.1 million. The company's cash position remains critically low and has slightly decreased, while total liabilities have reduced due to a gain on settlement of current liabilities.

Key Financial Figures

• $0.0001 — enting 2,000 Ordinary Shares, par value $0.0001 per share AKTX The Nasdaq Capital M

Filing Documents

• form10-q.htm (10-Q) — 1628KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-25-022390.txt ( ) — 8853KB
• aktx-20250930.xsd (EX-101.SCH) — 68KB
• aktx-20250930_cal.xml (EX-101.CAL) — 67KB
• aktx-20250930_def.xml (EX-101.DEF) — 357KB
• aktx-20250930_lab.xml (EX-101.LAB) — 563KB
• aktx-20250930_pre.xml (EX-101.PRE) — 463KB
• form10-q_htm.xml (XML) — 1503KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Shareholders' Equity (Deficit) 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39 PART II OTHER INFORMATION 41 Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41 Item 3. Defaults Upon Senior Securities 41 Item 4. Mine Safety Disclosures 41 Item 5. Other Information 41 Item 6. Exhibits 42

SIGNATURES

SIGNATURES 43 i GENERAL INFORMATION Unless otherwise stated or the context requires otherwise, references in this Quarterly Report on Form 10-Q ("Form 10-Q") to "Akari," the "company," the "Company," "we," "us," "our" or similar designations refer to Akari Therapeutics, Plc and its subsidiaries, taken together. All trademarks, service marks, trade names and registered marks used in this report are trademarks, trade names or registered marks of their respective owners. made in this Form 10-Q concerning the contents of any agreement, contract or other document are summaries of such agreements, contracts or documents and are not complete description of all of their terms. If we filed any of these agreements, contracts or documents as exhibits to this Form 10-Q or to any previous filing with the Securities and Exchange Commission ("SEC"), you may read the document itself for a complete understanding of its terms. ii NOTE REGARDING FORWARD-LOOKING STATEMENTS This Form 10-Q and the documents we incorporate by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of historical fact, included or incorporated in this report regarding, among other things, our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations, intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to our competitors and our industry, the timing or likelihood of regulatory actions, filings and approvals for our current and future drug candidates, and the plans and objectives of management are forward-looking statemen

Business

Business Overview Akari Therapeutics, Plc, (the "Company" or "Akari") is incorporated in the United Kingdom. The Company is developing next-generation antibody-drug conjugates, or ADCs, through its proprietary technology platform of novel payloads, enabling Akari to generate multiple ADC candidates to target a range of cancers. On March 4, 2024, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Peak Bio, Inc. ("Peak Bio") and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari ("Merger Sub"). On November 14, 2024, the Company completed the previously announced strategic business combination contemplated by the Merger Agreement ("Closing"), pursuant to which, Merger Sub merged with and into Peak Bio, with Peak Bio surviving the acquisition as a wholly owned subsidiary of Akari. Since the Company's acquisition of Peak Bio in November 2024, Akari has focused substantially all of its efforts on its ADC platform utilizing a novel anti-cancer payload called PH1, a spliceosome modulator. Through its payload platform, the Company aims to establish a pipeline of ADC candidates that target and directly kill cancer cells, while also activating the immune system to provide for potentially more durable and sustained efficacy and responses, thereby overcoming limitations inherent in existing ADC therapies. The Company's activities since inception have consisted of performing research and development activities and raising capital. The Company is subject to a number of risks similar to those of pre-clinical and clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual

View Full Filing

View this 10-Q filing on SEC EDGAR